Key Performance
More- Earnings Score: 34
- Momentum Score: 22
- True Yield: N/A
- Financial Health Score: 71
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences announced inducement equity awards to ten new employees on May 4, 2026, including stock options for 36,800 shares and restricted stock units for 27,700 shares. The awards were granted under the company's Amended and Restated 2014 Inducement Plan with an exercise price of $24.69 per share.
05/08/2026, 8:00 AM • GlobeNewswire
Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release
Pacira BioSciences CFO Shawn Cross exercised and sold 12,941 shares for approximately $326,000 on April 23, 2026, representing 10.94% of his direct holdings. The transaction was part of a pre-planned Rule 10b5-1 trading plan. Despite the insider sale, the company reported strong Q1 2026 results with $177 million in revenue (5% YoY growth) and beat analyst expectations, with the stock rising about 12% in April.
05/01/2026, 8:17 AM • The Motley Fool
Pacira BioSciences presented real-world data demonstrating that EXPAREL (bupivacaine liposome injectable suspension) is associated with lower total healthcare costs and reduced opioid utilization in outpatient total hip and knee arthroplasty procedures. Three studies showed cost savings ranging from $7,332 to $13,022 over 6 months post-surgery, with a projected cumulative cost difference of $117,868 per 1 million members by year 3 compared to ropivacaine.
04/13/2026, 8:00 AM • GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences announced inducement equity awards to three new employees on March 3, 2026, including stock options for 2,400 shares and restricted stock units for 5,500 shares. The awards were granted under the company's Amended and Restated 2014 Inducement Plan with an exercise price of $22.10 per share.
03/06/2026, 8:00 AM • GlobeNewswire
The global corticosteroids market is projected to grow from USD 6.24 billion in 2025 to USD 8.45 billion by 2031 at a CAGR of 5.18%, driven by rising chronic diseases like asthma and COPD. However, safety concerns from prolonged usage and a shift toward biologics and localized therapies present significant challenges. Innovations in drug delivery systems and extended-release formulations are reshaping the market.
01/26/2026, 4:51 AM • GlobeNewswire
Pacira BioSciences received a Paragraph IV Certification Notice from Qilu Pharmaceutical regarding a generic equivalent filing for EXPAREL, challenging 18 of Pacira's patents. Pacira intends to vigorously defend its intellectual property rights.
10/27/2025, 8:00 AM • GlobeNewswire
Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®
Pacira BioSciences will present research at AMCP Nexus 2025 highlighting the clinical effectiveness and economic benefits of EXPAREL, a non-opioid pain therapy, with multiple studies focusing on pain management in knee and shoulder surgeries.
10/23/2025, 8:00 AM • GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences granted inducement awards to 15 new employees, including 18,000 stock options and 32,600 restricted stock units, to incentivize new hires under their Inducement Plan.
10/03/2025, 8:00 AM • GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences granted stock options and restricted stock units to nine new employees under its Inducement Plan, with 13,000 stock options and 18,100 restricted stock units awarded.
09/05/2025, 8:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.